Highlights Novartis AG London S.E.

Equities

0QM7

CH0038459415

Delayed London S.E. Other stock markets 11:59:30 2018-05-21 EDT			5-day change	1st Jan Change
76.86 ^CHF	-1.00%		-0.77%	-.--%

06-24	Foreign banks target Switzerland after UBS takeover of Credit Suisse	RE
06-24	NOVARTIS AG : Barclays reaffirms its Sell rating	ZD

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Foreign banks target Switzerland after UBS takeover of Credit Suisse	06-24	RE
Factbox-European companies cut jobs as economy sputters	06-21	RE
Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15	06-20	DP
Novartis: towards the filing of a buyout offer for MorphoSys	06-20	CF
MorphoSys Set to Delist Following Acquisition by Novartis	06-20	MT
MorphoSys Inks Delisting Agreement After Takeover by Novartis	06-20	MT
Biotech company Morphosys will soon disappear from the stock exchange	06-20	RE
EU regulator mandates label updates on CAR-T cancer therapies	06-14	RE
PeptiDream and Novartis Agreement Becomes Effective with 28.3 Billion Yen Upfront Payment	06-14	MT
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment	06-13	CI
Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy	06-07	MT
Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug	06-07	MT
Novartis and others face Italy antitrust probe over eye drug	06-06	RE
Three newcomers to the MDax - Rational, TUI and Traton move up	06-06	RE
Cytokinetics CEO Says Board Would Have Backed Actionable Buyout	06-05	DJ
NOVARTIS : UBS reiterates buy recommendation after ASCO	06-03	CF
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	06-02	RE
European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected	05-31	MT
Swiss Market Index in the Green Amid US Rate Cut Optimism	05-31	MT
Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints	05-31	MT